Survodutide vs Retatrutide: Comparing the Dual and Triple Agonist Research Peptides

The first generation of GLP-1 drugs had a firm rule about the glucagon receptor: leave it switched off. Glucagon raises blood sugar, and a diabetes drug that pushes glucose up is a non-starter. So it looked almost backwards when the newest metabolic agonists deliberately switched glucagon back on. Survodutide and retatrutide are two of the clearest cases, and setting survodutide vs retatrutide side by side is a clean way to see why the glucagon arm came back into fashion.

Both are investigational peptide agonists studied in obesity and broader metabolic research, and neither is approved. Survodutide is a dual agonist - it activates the GLP-1 receptor and the glucagon receptor. retatrutide takes it a step further as a triple agonist, adding the GIP receptor to those same two. The shared ingredient is glucagon. The dividing line is that extra GIP arm. Both are acylated peptides too, each carrying a fatty-acid chain that stretches its half-life far enough to support once-weekly dosing in the studies that have tested them. If you want the standalone primer first, the retatrutide explainer covers the triple agonist on its own.

What the glucagon receptor brings

Glucagon is best known as insulin's counterweight - it tells the liver to release stored glucose. On its own, that is the last thing a metabolic drug wants. But glucagon does other things that turn out to be useful for weight and liver research. It raises energy expenditure, nudging the body to burn more fuel at rest. And it pushes the liver to oxidize fat, which can draw lipid out of an overloaded, fatty liver. That liver effect is why dual GLP-1 and glucagon agonists have drawn so much attention in MASH research, the condition once labelled NASH. The whole thing hinges on balance. Pair glucagon with GLP-1, and the GLP-1 side - which boosts insulin and blunts appetite - offsets glucagon's tendency to lift glucose, while the two together turn fat burning up and food intake down. The wider receptor story sits in the incretin and glucagon receptor overview.

Dual versus triple: what the GIP arm adds

GIP is the other major incretin hormone. Like GLP-1, it amplifies insulin release after a meal, and in the multi-agonist designs it appears to add to weight reduction and may soften the nausea that limits how hard the other arms can be pushed. Retatrutide stacks that GIP activity on top of the GLP-1 and glucagon combination survodutide already runs. So which one is better? That framing misses the point - these are two different bets. Survodutide asks how far a focused GLP-1 and glucagon pairing can go. Retatrutide asks what a third incretin arm buys on top. For a different angle on the same question, tirzepatide is a dual GIP and GLP-1 agonist with no glucagon at all, and the tirzepatide versus retatrutide breakdown shows how much the glucagon arm alone reshapes the profile.

Where the research actually stands

In mid-stage trials, both compounds posted numbers that made the field sit up. Studies of retatrutide reported weight reductions in the low-to-mid twenties as a percentage of body weight over roughly a year, among the steepest figures published for any single agonist. Survodutide's mid-stage obesity work reported reductions closer to the high teens, and separate MASH studies showed improvement in liver histology - which fits its glucagon-forward design. Its late-stage obesity research runs under the SYNCHRONIZE program, while the liver work was tested in a dedicated MASH trial that reported meaningful movement on the fibrosis and inflammation measures it set out to change. Read all of that as research findings rather than a scoreboard: trial designs, durations, and patient populations differ, so a straight head-to-head number would mislead more than it informs.

Neither compound is approved for any use. Survodutide, developed by Boehringer Ingelheim with Zealand Pharma, is in Phase 3 and carries no brand name of any kind. Retatrutide, Eli Lilly's LY3437943, is also in Phase 3. Any retatrutide offered for research is research-use-only material, sold for laboratory work and nothing else - a different category from an approved medicine, and not a substitute for one. You can see how both fit the wider field in the 2026 pipeline overview, and the research-grade compound itself sits in the catalog.

Research use only. This article is educational and is not medical, legal, or financial advice. The compounds discussed are not approved for human or veterinary use, consumption, or therapeutic application.